THIOCYANATE-BASED TOXICITY OF EOSINOPHIL PEROXIDASE
Project Number5R01HL048915-02
Contact PI/Project LeaderSLUNGAARD, ARNE
Awardee OrganizationUNIVERSITY OF MINNESOTA
Description
Abstract Text
Activated eosinophils (EOS) destroy parasites but can also damage host
tissue. Although the most common human disease caused by EOS is
allergies, the most catastrophic is eosinophilic endocarditis, the second
leading cause of cardiac deaths in tropical Africa and Asia. We have
unexpectedly found that the dietarily derived pseudohalide thiocyanate
(SCN), not Br as previously thought, is the primary substrate for the
unique eosinophil peroxidase (EPO) in physiologic fluids. This is a
provocative results because the product of this reaction, HOSCN, is a far
weaker oxidant than are the potent by nonspecific bleaching oxidants HOBr
and HOCl, the main product of neutrophil myeloperoxidase. We hypothesize
that precisely because of its restricted oxidant reactivity, HOSCN,
unlike membrane lytic HOBr and HOCI, penetrates intact membranes to
oxidize specific intracellular protein sulfhydryl (SHs). This SH-
specificity may endow HOSCN with the capacity to kill parasites
preferentially over host cells. However, in conditions of serum SCN-
depletion, EPO will instead oxidize Br to produce indiscriminantly toxic
HOBr, which severely damages adjacent host tissues. Thus, SCN-may both
mediated and modulate EO cytotoxicity. Our first specific aim is to show
that EOs physiologically activated by large opsonized particles produce
HOSCN. Our second specific aim is to define molecular mechanisms
underlying the direct toxicity of reagent HOSCN for EOs themselves, for
mammalian cells, and for schistosomules, a classical model of parasite
infestation. We hypothesize that HOSCN is a SH-specific metabolic
poison, and the glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is its principal target. Our third specific aim
is to characterize possible indirect mechanisms of HOSCN toxicity
involving secondary oxidative interactions with H2O2 other cationic
eosinophil granule proteins, proteases, and anti-proteases. Toxic as
HOSCN may be for host tissue, however, HOBr is at least tenfold more
lethal. Therefore our fourth specific aim is to characterize the halide
composition of serum from individuals with hypereosinophilia heart
disease. We hypothesize that such patients peroxidatively deplete their
own serum of SCN-, low levels of which are a risk factor for host tissue
damage by permitting EPO to oxidize Br to HOBr instead of SCN to HOSCN.
Our fifth specific aim is to establish a mouse model of eosinophilic
endocarditis utilizing transgenic mice that overexpress the eosinophil-
specific growth factor interleukin 5 (IL-5). We will examine the role
of SCN in regulating cardiac damage in this model by experimentally
augmenting of depleting serum SCN. These studies, if successful, will
define an important, hitherto unsuspected role for SCN- in governing the
toxicity of EOs for parasites and host tissues. If so, we will have
identified a simple therapeutic strategy for blunting host toxicity --
dietary supplementation of SCN -- that could be applied even in a Third
World.
No Sub Projects information available for 5R01HL048915-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL048915-02
Patents
No Patents information available for 5R01HL048915-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL048915-02
Clinical Studies
No Clinical Studies information available for 5R01HL048915-02
News and More
Related News Releases
No news release information available for 5R01HL048915-02
History
No Historical information available for 5R01HL048915-02
Similar Projects
No Similar Projects information available for 5R01HL048915-02